Management of Fluconazole and Apixaban Co-administration

Introduction to Fluconazole and Apixaban Interaction

• The American Heart Association recommends careful monitoring when co-administering fluconazole with apixaban due to a significant drug interaction that substantially increases bleeding risk, as fluconazole significantly increases apixaban levels through inhibition of CYP3A4 and CYP2C9 enzymes 1

Alternative Antifungal Agents

• The Infectious Diseases Society of America recommends echinocandins for moderately severe to severe candidemia, particularly in patients with recent azole exposure, as echinocandins lack significant CYP450 interactions and do not increase bleeding risk with apixaban 3
• For invasive candidiasis, echinocandins are preferred initial therapy in non-neutropenic patients, according to the Clinical Infectious Diseases guidelines 4

Fluconazole Dosing Considerations

• The Clinical Infectious Diseases guidelines recommend fluconazole 400 mg daily (after 800 mg loading dose) for candidemia without CNS involvement, and lower fluconazole doses (<200 mg/day) have reduced interaction potential but may compromise antifungal efficacy 5
• Fluconazole achieves excellent CSF and vitreous penetration (>50% of serum levels), making it irreplaceable for CNS and ocular candidiasis, as stated in the Clinical Infectious Diseases journal 5

Clinical Context Where Fluconazole May Be Unavoidable

• The Clinical Infectious Diseases guidelines state that fluconazole remains the preferred agent for specific indications despite the interaction, including CNS candidiasis or cryptococcal meningitis (fluconazole 400-800 mg daily after amphotericin B induction) 5
• The Clinical Infectious Diseases journal recommends fluconazole for Candida urinary tract infections (fluconazole achieves urine concentrations 10-20 times serum levels) 5

Monitoring and Dose Adjustment

• The Praxis Medical Insights guidelines suggest using the lowest effective fluconazole dose for the shortest duration necessary, and consider reducing apixaban dose (e.g., from 5 mg twice daily to 2.5 mg twice daily) in consultation with cardiology 3
• The Clinical Infectious Diseases guidelines recommend monitoring for signs of bleeding (bruising, hematuria, melena, hemoptysis) at each clinical encounter, and obtaining CBC weekly during the first 2-4 weeks of concurrent therapy 5